Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Visceral leishmaniasis: Clinical manifestations and diagnosis

Caryn Bern, MD, MPH
Section Editor
Peter F Weller, MD, MACP
Deputy Editor
Elinor L Baron, MD, DTMH


Visceral leishmaniasis (VL), also known as kala-azar, black fever, and Dumdum fever, is a disease primarily caused by Leishmania donovani and L. infantum (synonym L. chagasi) that is transmitted by sandflies (table 1) [1]. Rarely, visceral disease has been reported in patients infected with leishmanial species usually associated with cutaneous disease, in particular, L. mexicana and L. tropica [2-5]. The major clinical manifestations caused by L. donovani and L. infantum are not generally distinguishable, and specialized techniques are needed to identify the species. However, treatment decisions for VL usually do not require species identification since they are based on disease severity, geographic origin, and the presence of HIV and other coinfections.

Issues related to clinical manifestations and diagnosis of visceral leishmaniasis will be reviewed here. Issues related to epidemiology and treatment of VL are discussed separately. (See "Visceral leishmaniasis: Treatment" and "Visceral leishmaniasis: Epidemiology and control".)


Leishmania invade and replicate within host macrophages, evading innate and cell-mediated immune responses. Infection generally appears to persist after clinical cure of the primary infection [6,7]. Evasion and persistence are achieved through a combination of strategies including neutralization of complement components, preventing release of macrophage superoxide and nitric oxide, and suppressing induction of antigen-specific CD4+ T helper lymphocytes [7,8]. Spontaneous recovery is rare, although some relatively mild, self-limited cases of visceral leishmaniasis have been reported in a cohort of Brazilian children [9].


Asymptomatic infection — Many leishmaniasis infections are asymptomatic, reflecting the ability of the host immune system to control the parasite [10,11]. The ratio of asymptomatic infection to clinically manifest disease varies widely, from >30:1 in Europe to 6:1 in Brazilian children and 4:1 in Bangladesh. This may reflect differences in parasite virulence, human genetic predisposition, nutritional status, and other factors [11-18].

Subclinical infections can be detected early in their course with serologic testing. The later development of a protective cell-mediated immune response can be detected via leishmanin skin testing (see 'Diagnosis' below). The majority of patients with subclinical infection harbor viable parasites lifelong and can develop reactivation disease if immunosuppression occurs, although there does not appear to be a role for primary prophylaxis [6,19].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Dec 06, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH) (2016). http://cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw670.full.pdf+html (Accessed on November 16, 2016).
  2. Barral A, Badaró R, Barral-Netto M, et al. Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis. Am J Trop Med Hyg 1986; 35:732.
  3. Monroy-Ostria A, Hernandez-Montes O, Barker DC. Aetiology of visceral leishmaniasis in Mexico. Acta Trop 2000; 75:155.
  4. Sacks DL, Kenney RT, Kreutzer RD, et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345:959.
  5. Magill AJ, Grögl M, Gasser RA Jr, et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328:1383.
  6. Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 2008; 10:1221.
  7. Bogdan C, Röllinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 1998; 28:121.
  8. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83:1253.
  9. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154:1003.
  10. Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.696.
  11. Singh OP, Hasker E, Sacks D, et al. Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clin Infect Dis 2014; 58:1424.
  12. Bern C, Haque R, Chowdhury R, et al. The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village. Am J Trop Med Hyg 2007; 76:909.
  13. Badaró R, Jones TC, Lorenço R, et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 1986; 154:639.
  14. Moral L, Rubio EM, Moya M. A leishmanin skin test survey in the human population of l'Alacantí region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg 2002; 96:129.
  15. Anstead GM, Chandrasekar B, Zhao W, et al. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect Immun 2001; 69:4709.
  16. Blackwell JM, Fakiola M, Ibrahim ME, et al. Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol 2009; 31:254.
  17. Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 1987; 156:1030.
  18. Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70:6919.
  19. de Rossell RA, de Duran RJ, Rossell O, Rodríguez AM. Is leishmaniasis ever cured? Trans R Soc Trop Med Hyg 1992; 86:251.
  20. Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000; 63:184.
  21. Baba CS, Makharia GK, Mathur P, et al. Chronic diarrhea and malabsorption caused by Leishmania donovani. Indian J Gastroenterol 2006; 25:309.
  22. Magill AJ. Visceral leishmaniasis (kala-azar). In: Hunter's Tropical Medicine and Emerging Infectious Diseases, 8th ed, Strickland GT (Ed), W.B.Saunders Company, Philadelphia 2000. p.670.
  23. Andrade TM, Carvalho EM, Rocha H. Bacterial infections in patients with visceral leishmaniasis. J Infect Dis 1990; 162:1354.
  24. Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229.
  25. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996; 14:417.
  26. Sen Gupta PC. History of kala-azar in India. Indian Medical Gazette 1947; 82:281.
  27. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996; 25:862.
  28. Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612.
  29. Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 2005; 11:655.
  30. Rey LC, Martins CV, Ribeiro HB, Lima AA. American visceral leishmaniasis (kala-azar) in hospitalized children from an endemic area. J Pediatr (Rio J) 2005; 81:73.
  31. Pandey K, Sinha PK, Ravidas VN, et al. Nexus of infection with human immunodeficiency virus, pulmonary tuberculosis and visceral leishmaniasis: a case report from Bihar, India. Am J Trop Med Hyg 2005; 72:30.
  32. Herrero M, Orfanos G, Argaw D, et al. Natural history of a visceral leishmaniasis outbreak in highland Ethiopia. Am J Trop Med Hyg 2009; 81:373.
  33. Mueller Y, Mbulamberi DB, Odermatt P, et al. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 2009; 14:910.
  34. Duarte MI, Silva MR, Goto H, et al. Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 1983; 77:531.
  35. Dutra M, Martinelli R, de Carvalho EM, et al. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6:22.
  36. Libório AB, Rocha NA, Oliveira MJ, et al. Acute kidney injury in children with visceral leishmaniasis. Pediatr Infect Dis J 2012; 31:451.
  37. Lima Verde FA, Lima Verde FA, Lima Verde IA, et al. Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. J Nephrol 2007; 20:430.
  38. Costa FA, Guerra JL, Silva SM, et al. CD4(+) T cells participate in the nephropathy of canine visceral leishmaniasis. Braz J Med Biol Res 2000; 33:1455.
  39. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol 2013; 139:713.
  40. Rajagopala S, Dutta U, Chandra KS, et al. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis--case report and systematic review. J Infect 2008; 56:381.
  41. http://journals.lww.com/pidj/Abstract/2015/12000/Hemophagocytic_Syndrome_in_Children_With_Visceral.7.aspx (Accessed on December 08, 2015).
  42. Kager PA, Rees PH. Haematological investigations in visceral leishmaniasis. Trop Geogr Med 1986; 38:371.
  43. Werneck GL, Batista MS, Gomes JR, et al. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31:174.
  44. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951.
  45. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334.
  46. van Griensven J, Zijlstra EE, Hailu A. Visceral leishmaniasis and HIV coinfection: time for concerted action. PLoS Negl Trop Dis 2014; 8:e3023.
  47. Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 1992; 86:505.
  48. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 2005; 72:811.
  49. Lightner LK, Chulay JD, Bryceson AD. Comparison of microscopy and culture in the detection of Leishmania donovani from splenic aspirates. Am J Trop Med Hyg 1983; 32:296.
  50. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32:475.
  51. Gatti S, Gramegna M, Klersy C, et al. Diagnosis of visceral leishmaniasis: the sensitivities and specificities of traditional methods and a nested PCR assay. Ann Trop Med Parasitol 2004; 98:667.
  52. López-Vélez R, Laguna F, Alvar J, et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1995; 33:937.
  53. Hide M, Singh R, Kumar B, et al. A microculture technique for isolating live Leishmania parasites from peripheral blood of visceral leishmaniasis patients. Acta Trop 2007; 102:197.
  54. Cruz I, Cañavate C, Rubio JM, et al. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 2002; 96 Suppl 1:S185.
  55. le Fichoux Y, Quaranta JF, Aufeuvre JP, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999; 37:1953.
  56. Osman OF, Oskam L, Zijlstra EE, et al. Evaluation of PCR for diagnosis of visceral leishmaniasis. J Clin Microbiol 1997; 35:2454.
  57. Salotra P, Sreenivas G, Pogue GP, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol 2001; 39:849.
  58. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 2007; 45:21.
  59. Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol 2006; 44:2343.
  60. Antinori S, Calattini S, Longhi E, et al. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis 2007; 44:1602.
  61. Galvão-Castro B, Sá Ferreira JA, Marzochi KF, et al. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin Exp Immunol 1984; 56:58.
  62. el Harith A, Kolk AH, Leeuwenburg J, et al. Improvement of a direct agglutination test for field studies of visceral leishmaniasis. J Clin Microbiol 1988; 26:1321.
  63. Reed SG, Shreffler WG, Burns JM Jr, et al. An improved serodiagnostic procedure for visceral leishmaniasis. Am J Trop Med Hyg 1990; 43:632.
  64. Badaró R, Benson D, Eulálio MC, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996; 173:758.
  65. Badaró R, Reed SG, Barral A, et al. Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg 1986; 35:72.
  66. Qu JQ, Zhong L, Masoom-Yasinzai M, et al. Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans R Soc Trop Med Hyg 1994; 88:543.
  67. Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 2006; 333:723.
  68. Cunningham J, Hasker E, Das P, et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 2012; 55:1312.
  69. Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev 2014; :CD009135.
  70. Sundar S, Maurya R, Singh RK, et al. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol 2006; 44:251.
  71. Sundar S, Reed SG, Singh VP, et al. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1998; 351:563.
  72. Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 1998; 177:1339.
  73. Chappuis F, Rijal S, Jha UK, et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop Med Int Health 2006; 11:31.
  74. Chappuis F, Mueller Y, Nguimfack A, et al. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 2005; 43:5973.
  75. Bern C, Amann J, Haque R, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg 2006; 75:744.
  76. MANSON-BAHR PE. Immunity in kala-azar. Trans R Soc Trop Med Hyg 1961; 55:550.
  77. Zijlstra EE, el-Hassan AM. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar. Trans R Soc Trop Med Hyg 1993; 87:425.
  78. Neogy AB, Nandy A, Dastidar BG, Chowdhury AB. Leishmanin test in Indian kala-azar. Trans R Soc Trop Med Hyg 1986; 80:454.
  79. Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 2008; 102:32.
  80. Sundar S, Agrawal S, Pai K, et al. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am J Trop Med Hyg 2005; 73:269.
  81. Sundar S, Singh RK, Bimal SK, et al. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. Trop Med Int Health 2007; 12:284.
  82. Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3:87.
  83. Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995; 34:85.
  84. Ramesh V. On the differences between post-kala-azar dermal leishmaniasis and leprosy. Trop Doct 1994; 24:120.
  85. Ansari NA, Ramesh V, Salotra P. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis 2006; 194:958.
  86. Sreenivas G, Raju BV, Singh R, et al. DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal Leishmaniasis in humans. J Clin Microbiol 2004; 42:1739.
  87. Rahman KM, Islam S, Rahman MW, et al. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh. Clin Infect Dis 2010; 50:73.
  88. Salotra P, Singh R. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res 2006; 123:295.
  89. Salotra P, Sreenivas G, Beena KR, et al. Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods. J Clin Pathol 2003; 56:840.
  90. Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis 2014; 59:552.
  91. Pintado V, Martín-Rabadán P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80:54.
  92. Alvar J, Cañavate C, Gutiérrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298.
  93. Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000; 31:1093.
  94. Mota Sasaki Md, Matsumo Carvalho M, Schmitz Ferreira ML, Machado MP. Cutaneous Leishmaniasis Coinfection in AIDS Patients: Case Report and Literature Review. Braz J Infect Dis 1997; 1:142.
  95. González-Beato MJ, Moyano B, Sánchez C, et al. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis. Br J Dermatol 2000; 143:1316.
  96. Cánovas DL, Carbonell J, Torres J, et al. Laryngeal leishmaniasis as initial opportunistic disease in HIV infection. J Laryngol Otol 1994; 108:1089.
  97. Miralles ES, Núñez M, Hilara Y, et al. Mucocutaneous leishmaniasis and HIV. Dermatology 1994; 189:275.
  98. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on September 21, 2016).
  99. Medrano FJ, Cañavate C, Leal M, et al. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998; 59:155.